Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTS-270 Safety and Tolerability in Pediatric NPC (< 4 Years)
NCT03687476Phase 2Withdrawn
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- May 2020
- Primary completion
- Oct 2022
- Modality
- Nanoparticles, Small Molecules
01
Overview
A Phase 2 trial of Trappsol Cyclo in Niemann-Pick disease type C (NPC), sponsored by Mallinckrodt Pharmaceuticals. Planned start May 2020; status: withdrawn.
02
Drugs
Trappsol Cyclo
03
Conditions
Niemann-Pick disease type C (NPC)
Beyond the preview
Go deeper on NCT03687476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03687476.